NexgenRx Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
For the six months, revenue was CAD 6.29 million compared to CAD 5.56 million a year ago. Net income was CAD 0.408024 million compared to CAD 0.742217 million a year ago. Basic earnings per share from continuing operations was CAD 0.006 compared to CAD 0.011 a year ago. Diluted earnings per share from continuing operations was CAD 0.005 compared to CAD 0.01 a year ago.